Department 3rd of Internal Medicine, Semmelweis University, Budapest, Hungary.
Department of Pathogenetics, National Institute of Oncology, Budapest, Hungary.
Sci Rep. 2017 Sep 5;7(1):10462. doi: 10.1038/s41598-017-09058-8.
Mannan-binding lectin-associated serine protease 1 (MASP-1), the most abundant enzyme of the complement lectin pathway, is able to stimulate human umbilical vein endothelial cells (HUVECs) to alter the expression of several cytokines and adhesion molecules. This study has assessed to what extent MASP-1 is able to modify the transcriptional pattern of inflammation-related (IR) genes in HUVECs. We utilized Agilent microarray to analyse the effects of recombinant MASP-1 (rMASP-1) in HUVECs, on a set of 884 IR genes. Gene Set Enrichment Analysis showed an overall activation of inflammation-related genes in response to rMASP-1. rMASP-1 treatment up- and down-regulated 19 and 11 IR genes, respectively. Most of them were previously unidentified, such as genes of chemokines (CXCL1, CXCL2, CXCL3), inflammatory receptors (TLR2, BDKRB2) and other inflammatory factors (F3, LBP). Expression of IR genes changed early, during the first 2 hours of activation. Both p38-MAPK inhibitor and NFκB inhibitor efficiently suppressed the effect of rMASP-1. We delineated 12 transcriptional factors as possible regulators of rMASP-1-induced IR genes. Our microarray-based data are in line with the hypothesis that complement lectin pathway activation, generating active MASP-1, directly regulates inflammatory processes by shifting the phenotype of endothelial cells towards a more pro-inflammatory type.
甘露聚糖结合凝集素相关丝氨酸蛋白酶 1(MASP-1)是补体凝集素途径中最丰富的酶,能够刺激人脐静脉内皮细胞(HUVEC)改变几种细胞因子和粘附分子的表达。本研究评估了 MASP-1 在多大程度上能够改变 HUVEC 中炎症相关(IR)基因的转录模式。我们利用安捷伦微阵列分析了重组 MASP-1(rMASP-1)对 HUVEC 中一组 884 个 IR 基因的影响。基因集富集分析显示,rMASP-1 对炎症相关基因有整体激活作用。rMASP-1 处理分别上调和下调了 19 个和 11 个 IR 基因。其中大多数以前未被识别,如趋化因子(CXCL1、CXCL2、CXCL3)、炎症受体(TLR2、BDKRB2)和其他炎症因子(F3、LBP)的基因。IR 基因的表达在激活的前 2 小时内就发生了变化。p38-MAPK 抑制剂和 NFκB 抑制剂均能有效抑制 rMASP-1 的作用。我们确定了 12 个转录因子作为 rMASP-1 诱导的 IR 基因的可能调节剂。我们基于微阵列的数据与以下假设一致,即补体凝集素途径的激活产生有活性的 MASP-1,通过将内皮细胞的表型向更具炎症性的类型转变,直接调节炎症过程。